Sandbox Reserved 958: Difference between revisions
No edit summary |
No edit summary |
||
| Line 47: | Line 47: | ||
[[Image:1742-4690-7-18-7.jpg]] | [[Image:1742-4690-7-18-7.jpg]] | ||
In contrary '''Ku70 reduces the ubiquitination level''' of the N-ter domain (K6, K11, K27, K29, K33, K48 and K63). Another study also found that IN contains three ψ-K-x-D/E motifs, which can be SUMOylated at three Lys residues, K46,<scene name='60/604477/Sumoylation/1'>K136</scene> and K244 <ref name="Terreni">PMID:20226045</ref>. | In contrary '''Ku70 reduces the ubiquitination level''' of the N-ter domain (K6, K11, K27, K29, K33, K48 and K63). Another study also found that IN contains '''three ψ-K-x-D/E motifs''', which can be SUMOylated at three Lys residues, K46,<scene name='60/604477/Sumoylation/1'>K136</scene> and K244 <ref name="Terreni">PMID:20226045</ref>. | ||
==Inhibitors== | ==Inhibitors== | ||
Since few years, HIV-1 is an important therapeutic target. Actually there are two kind of inhibitors: the '''I'''ntegrase '''S'''trand '''T'''ransfer '''I'''nhibitors ('''INSTIs''' ) and the '''IN'''tegrase DNA-'''B'''inding '''I'''nhibitors '''(INBIs)'''. Over the past 5 years, INSTIs have been shown significant results as antiviral compounds with in 2007, the licensing of the first integrase inhibitor called '''raltegravir''', which target the integrase active site and thus, inhibit DNA strand transfer. However, resistance to this compound emerges which in turn confers the same effect to the second licensed INSTI, '''elvitegravir'''<ref name="Engelman">PMID: 23647983</ref>. | Since few years, HIV-1 is an important therapeutic target. Actually there are two kind of inhibitors: the '''I'''ntegrase '''S'''trand '''T'''ransfer '''I'''nhibitors ('''INSTIs''' ) and the '''IN'''tegrase DNA-'''B'''inding '''I'''nhibitors '''(INBIs)'''. Over the past 5 years, INSTIs have been shown significant results as antiviral compounds with in 2007, the licensing of the first integrase inhibitor called '''raltegravir''', which target the integrase active site and thus, inhibit DNA strand transfer. However, resistance to this compound emerges which in turn confers the same effect to the second licensed INSTI, '''elvitegravir'''<ref name="Engelman">PMID: 23647983</ref>. | ||